Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Acellular fish skin graft for diabetic foot ulcers

Discussion in 'Diabetic Foot & Wound Management' started by NewsBot, Feb 16, 2019.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    Treatment of diabetic foot wounds with acellular fish skin graft rich in omega-3: a prospective evaluation.
    Woodrow T, Chant T, Chant H
    J Wound Care. 2019 Feb 2;28(2):76-80.
     
  2. DaVinci

    DaVinci Well-Known Member

    Did I read that right? Fish? WTF?
     
  3. Craig Payne

    Craig Payne Moderator

    Articles:
    8
    No control group … fishy ..
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    A Multicenter, Blinded, Randomized Controlled Clinical Trial Evaluating the Effect of Omega-3-Rich Fish Skin in the Treatment of Chronic, Nonresponsive Diabetic Foot Ulcers
    Eric J Lullove et al
    Wounds. 2021 Apr 14
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Faster Than Projected Healing in Chronic Venous and Diabetic Foot Ulcers When Treated with Intact Fish Skin Grafts Compared to Expected Healing Times for Standard of Care: An Outcome-Based Model from a Swiss Hospital
    Thomas Zehnder, Marlise Blatti
    Int J Low Extrem Wounds. 2022 May 12
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Evaluating the effect of omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers: penultimate analysis of a multicenter, prospective, randomized controlled trial
    Eric J Lullove et al
    Wounds. 2022 Apr;34(4):E34-E36.
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Final efficacy and cost analysis of a fish skin graft vs standard of care in the management of chronic diabetic foot ulcers: a prospective, multicenter, randomized controlled clinical trial
    John C Lantis Ii et al
    Wounds. 2023 Apr;35(4):71-79
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Intact Fish Skin Graft to Treat Deep Diabetic Foot Ulcers
    Dured Dardari et al
    NEJM Evid 2024 Oct 4
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Study Demonstrates Superiority of Kerecis Fish-Skin for Diabetic Foot Ulcer Treatment
    New England Journal of Medicine Evidence Publishes Results of the Largest Randomized Controlled Trial of its Kind
    Kerecis, the pioneer in the use of fish-skin and fatty acids for tissue regeneration and protection, today announced the publication of breakthrough study results in the New England Journal of Medicine Evidence. The study was conducted on a sample of 255 patients at 15 care centers across four countries. The study is the largest randomized controlled trial published to date on the efficacy of using biologic skin substitutes to treat foot ulcers with exposed bone and tendons. The study demonstrates that fish-skin grafts significantly outperform the standard of care in closing University of Texas grade 2 and 3 diabetic foot ulcers.

    Kerecis’s presentation of the study results met with an overwhelmingly positive reception during the Symposium on Advanced Wound Care (SAWC) held this month in Las Vegas.

    Key findings from this first-of-its-kind study

    This study – named Odinn as an homage to the Norse god of healing and wisdom – is by far the largest randomized controlled trial (RCT) of its kind because of the number of patients and severity of the wounds studied (University of Texas grades 2 and 3). The findings underscore the efficacy of fish-skin grafts in the treatment of diabetic foot ulcers (DFU), offering new hope and improved outcomes for patients.

    Key Study Findings:

    Significantly higher healing rates: At 16 weeks, 44% of DFUs treated with Kerecis Fish-skin Grafts had healed, compared with 26.4% using SOC (p<0.001).
    Sustained superiority: This trend continued, with 55.2% of fish-skin graft-treated wounds healed at 24 weeks versus 37.8% for standard care.
    Faster healing: In the study, diabetic foot ulcers treated with intact fish-skin graft were associated with faster wound closure time, with the wounds healing approximately two weeks earlier and with a 1.6x (95% CI: 1.07 - 2.36) greater chance of wound closure at any time point.
    University of Texas Grade 2 DFUs are serious wounds that penetrate deeply into the foot, reaching the tendon or capsule and involve subcutaneous tissues. Due to their depth and complexity, these ulcers require more intensive treatment. Grade 3 DFUs are even more severe, extending to the bone or joints and posing a higher risk of serious complications, such as infections and amputations. Due to their critical nature, Grade 3 DFUs often require aggressive and specialized treatment.

    DFUs are chronic, life-threatening conditions characterized by difficult and delayed healing. The consequences of these wounds are often severe, resulting in amputation and increased mortality rates as well as the clinical and fiscal impact of DFUs on patients' lives.

    The study was funded through a competitive grant from the European Union's Horizon 2020 research and innovation program.

    Results may transform wound treatment

    Kerecis Scientific Advisory Board Chairman John Lantis, MD says the study is truly a landmark. “The Odinn Trial is pivotal in diabetic foot ulcer treatment, especially for the more complex grades 2 and 3 cases. It provides compelling evidence that fish skin grafts could redefine the standard of care. With rigorous methodology and strong results, Odinn paves the way for a promising shift in clinical practice, where fish skin treatment may soon become the go-to option for managing severe diabetic foot ulcers, ultimately leading to better patient outcomes and quality of life.”

    Fertram Sigurjonsson, founder and CEO of Kerecis, says, “By conducting the largest RCT for complex DFUs that expose bone, tendon, or joints to date, we are breaking new ground in treatment of serious wounds and tissue damage. I am very proud to bring hope to patients who face the highest risks of complications and amputations, showing that innovative solutions can truly transform lives. Our team is committed to bringing our revolutionary treatment to healthcare providers and patients around the world, working toward our mission of making the Kerecis fish-skin the standard of care for serious wounds worldwide.”

    Healthcare providers specializing in wound care, podiatry, and diabetic foot care are encouraged to visit www.kerecis.com/publication to learn more about the groundbreaking findings and the efficacy of fish-skin grafts in treating wound and tissue damage.

    Media Note: For additional information about this study, information on 50 additional studies on the efficacy and benefits of fish-skin grafts, or to schedule an interview, contact the Media Relations Agency at (952) 697 5220. Link to study: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400171

    About Kerecis
    Kerecis, founded by Fertram Sigurjonsson, develops fish-skin and fatty acid products for cellular therapy, tissue regeneration, and protection. The patented material supports healing and regeneration when grafted onto damaged tissue, with no disease-transfer risk between cold-water fish and humans. The fish-skin is gently processed to maintain its natural structure, strength, and molecules. Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-skin and is the fastest growing company in the U.S. biologics skin market. Products include SurgiBind®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainable Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information, visit https://www.kerecis.com.
     
  10. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Acellular fish skin grafts in diabetic foot ulcer care: Advances and clinical insights
    Yu Zhao , Quan-Quan Shen
    World J Diabetes. 2025 Jan 15;16(1):100597.
     
Loading...

Share This Page